Andrew D. Zelenetz

Hematology | Oncology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 210 publications

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 29, 2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances
Published: February 24, 2026

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Journal: Blood advances
Published: January 05, 2026

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Journal: Cancers
Published: November 28, 2025

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Journal: Cancers
Published: November 27, 2025

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Journal: Blood advances
Published: August 27, 2025

Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Journal: Blood advances
Published: August 27, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: August 20, 2025

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Journal: Leukemia & lymphoma
Published: July 02, 2025

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Journal: Blood advances
Published: June 18, 2025
Showing 1-12 of 210

Last Updated: 09/26/2026